J. Gurtler

发表

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors : assessment of safety and tolerability in a phase I, open-label expansion study

Manish R. Patel, K. Kelly, J. Infante, 2015 .

Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: A phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy.

K. Kelly, G. Weiss, A. Heydebreck, 2015 .

Evaluation of the relationship between cetuximab therapy and corrected QT interval changes in patients with advanced malignancies from solid tumors

H. Lu, J. Deeken, O. Trifan, 2013, Cancer Chemotherapy and Pharmacology.

Randomized multicenter phase II trial of bolus plus infusional fluorouracil/leucovorin compared with fluorouracil/leucovorin plus oxaliplatin as third-line treatment of patients with advanced colorectal cancer.

A. Benson, N. Kemeny, H. Hochster, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Maintenance therapy with avelumab (MSB0010718C; anti-PD-L1) vs continuation of first-line chemotherapy in patients with unresectable, locally advanced or metastatic gastric cancer: The phase 3 JAVELIN Gastric 100 trial.

J. Taieb, N. Boku, J. Gurtler, 2016 .

CD20-negative relapse of cutaneous B-cell lymphoma after anti-CD20 monoclonal antibody therapy.

E. McBurney, J. Gurtler, William Trent Massengale, 2002, Journal of the American Academy of Dermatology.

Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens

V. Semiglazov, S. Tjulandin, L. Goldstein, 2005 .

Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study

L. Dirix, L. Emens, M. Lippman, 2017, Breast Cancer Research and Treatment.

A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma

H. Lenz, E. Rowinsky, A. Ko, 2012, Investigational New Drugs.

Trabectedin as a single-agent treatment of advanced breast cancer after anthracycline and taxane treatment: a multicenter, randomized, phase II study comparing 2 administration regimens.

V. Semiglazov, E. Bayever, S. Tjulandin, 2014, Clinical breast cancer.

A phase 2, single‐arm study of ramucirumab in patients with metastatic renal cell carcinoma with disease progression on or intolerance to tyrosine kinase inhibitor therapy

T. Choueiri, G. Hudes, W. Stadler, 2014, Cancer.

A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

R. Jain, A. Zhu, R. Finn, 2013, Clinical Cancer Research.

Supporting Patients with Cancer after Dobbs v. Jackson Women’s Health Organization

E. Bruera, C. la Vecchia, F. Hirsch, 2022, The oncologist.

Avelumab (MSB0010718C; anti-PD-L1) + best supportive care (BSC) vs BSC ± chemotherapy as third-line treatment for patients with unresectable, recurrent, or metastatic gastric cancer: The phase 3 JAVELIN Gastric 300 trial.

Y. Bang, F. Ciardiello, L. Wyrwicz, 2016 .

A phase II study of ramucirumab as first-line monotherapy in patients (pts) with advanced hepatocellular carcinoma (HCC).

A. Zhu, R. Finn, M. Mulcahy, 2010 .

Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial

R. Greil, O. Popovych, C. Gridelli, 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

Absence of interaction of cabazitaxel on the pharmacokinetics of midazolam: Results of a drug-drug interaction study in patients with advanced solid tumors.

S. Ross, A. Lockhart, C. Hsueh, 2013, Journal of Clinical Oncology.

An uncontrolled phase II study evaluating anti-tumor efficacy and safety of ortataxel (BAY 59-8862) in patients with taxane-resistant non-small cell lung cancer.

J. von Pawel, D. Voliotis, M. Moscovici, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.